Abdul Ingar
Abdul Ingar has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Anaïs F. M. Noisier
Medicinal Chemistry CVRM, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
2 shared publications - Gian Marco Ghiandoni
Augmented DMTA Platform, Data Analytics and AI, R&D IT, AstraZeneca, The Discovery Centre (DISC), Cambridge, UK
2 shared publications - Hannah L. Bolt
Department of Chemistry, Durham University, South Road, Durham, DH1 3LE, United Kingdom
2 shared publications - Johan Broddefalk
Medicinal Chemistry CVRM, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
2 shared publications - Kevin Pinto-Gil
Augmented DMTA Platform, R&D IT, AstraZeneca, Avenue Roma 81, 08029 Barcelona, Spain
2 shared publications - Lars Brive
Augmented DMTA Platform, R&D IT, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden
2 shared publications
Latest Publications
- Open Access
- 5 July 2026
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 66 (14) , 7821-7839
Advancing Biochemical Molecule Registration, Representation and Search for New Drug Modalities
The pharmaceutical industry’s shift toward new drug modalities, including therapeutic peptides, modified oligonucleotides, and antibody–drug conjugates, has exposed fundamental gaps in cheminformatics infrastructure. Unlike small molecules, which benefit from mature representation standards and reliable data exchange, new modalities lack robust and interoperable systems capable of capturing their structural and chemical complexity. Drawing on our experience at AstraZeneca, we examine these challenges across peptides, oligonucleotides, and ADCs, focusing on the limitations of current approaches, particularly HELM. We show that these limitations arise from both technical constraints, as new modalities exceed the scope of purely atomistic or sequence-based representations, and organizational gaps, including unresolved standardization and governance. We argue that local solutions exacerbate fragmentation, and that vendor- and community-driven standards, open implementations, and stronger governance are required to enable standardized and interoperable chemical information systems for next-generation therapeutics.
- 5 July 2026
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 66 (14) , 7821-7839
Open AccessAdvancing Biochemical Molecule Registration, Representation and Search for New Drug Modalities
The pharmaceutical industry’s shift toward new drug modalities, including therapeutic peptides, modified oligonucleotides, and antibody–drug conjugates, has exposed fundamental gaps in cheminformatics infrastructure. Unlike small molecules, which benefit from mature representation standards and reliable data exchange, new modalities lack robust and interoperable systems capable of capturing their structural and chemical complexity. Drawing on our experience at AstraZeneca, we examine these challenges across peptides, oligonucleotides, and ADCs, focusing on the limitations of current approaches, particularly HELM. We show that these limitations arise from both technical constraints, as new modalities exceed the scope of purely atomistic or sequence-based representations, and organizational gaps, including unresolved standardization and governance. We argue that local solutions exacerbate fragmentation, and that vendor- and community-driven standards, open implementations, and stronger governance are required to enable standardized and interoperable chemical information systems for next-generation therapeutics.
- Open Access
- 15 April 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Non-natural amino acid nomenclature for HELM monomer registration
The growing interest in studying modified and cyclic peptides is constrained by limitations in how their chemical information is encoded, represented, and analysed. Traditional sequence formats such as FASTA only allow working with linear and natural peptides. HELM and BILN formats provide more versatile and extendible notation systems for the representation of peptides with non-natural monomers or cyclic arrangements. HELM is a notation that uses a database as a source of monomers where these are defined on their structure, identifier, and attachment points. While structural representations are canonicalized using established methods, there is currently no widely accepted convention for naming peptide monomers. In this manuscript, we develop on top of the guidelines proposed by Pistoia Alliance for the naming of non-natural amino acids for their representation using HELM. Our nomenclature extends on modifications of side chains and backbone, naming of homo amino acids and peptoids, and resolves ambiguous cases using a combination of systematic and pragmatic rules.
- 15 April 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessNon-natural amino acid nomenclature for HELM monomer registration
The growing interest in studying modified and cyclic peptides is constrained by limitations in how their chemical information is encoded, represented, and analysed. Traditional sequence formats such as FASTA only allow working with linear and natural peptides. HELM and BILN formats provide more versatile and extendible notation systems for the representation of peptides with non-natural monomers or cyclic arrangements. HELM is a notation that uses a database as a source of monomers where these are defined on their structure, identifier, and attachment points. While structural representations are canonicalized using established methods, there is currently no widely accepted convention for naming peptide monomers. In this manuscript, we develop on top of the guidelines proposed by Pistoia Alliance for the naming of non-natural amino acids for their representation using HELM. Our nomenclature extends on modifications of side chains and backbone, naming of homo amino acids and peptoids, and resolves ambiguous cases using a combination of systematic and pragmatic rules.